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Abstract: The formation of nitric oxide
(NO), a free radical, increases in liver
disease, where the L-arginine-nitric oxide (Larg-NO) pathway is activated by the increased
levels of cytokines and endotoxins. In this
study, we investigated the relationship
between the L-arg-NO pathway and chronic
active hepatitis and cirrhosis, which are
classified as chronic liver disease. We
determined the serum levels of nitrite and
nitrate, the end products of the L-arg-NO
pathway, in patients with chronic liver
disease and compared them with the control
group levels.
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Total nitrite produced by the reduction of
nitrate to nitrite in the presence of nitrate
reductase was determined. The measurement
of nitrite concentrations was based on the
Griess reaction. The nitrate concentrations
were obtained by subtracting the nitrite
concentrations from the total nitrite+nitrate
concentration.
The study group consisted of 21 patients
with chronic active hepatitis and 19 patients
with cirrhosis. In the cirrhosis group, serum

Introduction
Chronic active hepatitis and cirrhosis are classified as
chronic liver disease. The hepatic failure is characterized
by specific, progressive, and often irreversible defects in
the hepatocellular metabolism (1). Cirrhotic patients
exhibit characteristic hemodynamic dysfunction
manifested by tendency to arterial hypotension. They
show systemic and splanchnic vascular resistance. These
changes have been attributed to the excessive production
or the decreased metabolism of an as-yet-undetermined
endogenous vasodilator substance. Several vasodilator
agents have been implicated so far, including prostacyclin,

levels of nitrite+nitrate, nitrate and nitrite
were 84.8±9.43 µmol/L, 74.75±9.49
µmol/L
and
10.03±1.59
µmol/L,
respectively. In the chronic active hepatitis
group, the values were 72.79±6.9 µmol/L,
59.9±7.09 µmol/L and 12.88±1.65 µmol/L,
respectively. The control group values
obtained from 10 normal persons were
29.0±4.6 µmol/L, 19.41± 3.16 µmol/L and
9.59±1.60 µmol/L, respectively.
The statistical evaluation showed a significant
difference between the control and study
groups (p <0.0001). We found higher
nitrite+nitrate and nitrate levels in the study
group than in the control group. Nitrite levels
did not show any significant difference
between the two groups. No significant
differences were found between the chronic
active hepatitis and cirrhosis groups (p>0.5).
Our results show that serum nitrite and
nitrate concentrations as an index of NO
generation may be elevated in hepatic failure
seen in chronic liver disease.
Key Words: Nitric oxide, chronic liver
disease, nitrate and nitrite

glucagon, vasointestinal peptide, substance P, false
neurotransmitters, atrial natriuretic peptide, plateletactivating factor and endotoxin, but none of them
convincingly explains the hemodynamic disturbances seen
in cirrhosis (2,3,4).
Nitric oxide (NO), a vasodilator generated from the
terminal guanido nitrogen of L-arginine by an N-hydoxylL-arginine intermediate yielding citrulline and catalyzed by
nitric oxide synthase (EC. 1.14.13.39) (2), accounts for
the biological activity of endothelium-derived relaxing
factor (5,6). Nitric oxide synthase activity has been
reported in many tissues, including endothelium (7,8,9),
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cerebellum (10,11) and myocardium (12). In the case of
chronic hepatitis, circulating levels of cytokines, such as
TNFα and IL6, increase during disease (13). In many
studies enhanced hepatic expression of a variety of
different cytokines has been demonstrated in patients
with hepatic inflammation. Many studies demonstrated
that hepatocytes express iNOS following exposure to
various cytokines such as tumor necrosis factor (TNF),
interleukin 1(IL1), interferon gamma (IFNγ), and
interleukin six (IL6) (14,15,16). Furthermore, it was
demonstrated that hepatocytes also produce NO in vivo
during chronic hepatic inflammation (17,18) and in vitro
in response to conditioned Kupffer cell supernatant (19)
or to a mixture of lipopolysaccharide (LPS) (20) and the
cytokines TNFα, IL1, and IFNγ (21). Human hepatocytes
were also stimulated to produce NO by the same
combination of endotoxin and cytokines as rat
hepatocytes (5,6,22). Increased NO production and
plasma nitrite/nitrate levels are also found during chronic
hepatic inflammation, suggesting a role for NO in the
hepatic response to inflammatory stimuli (23). The
reason for the vasodilation observed in endotoxoemia and
the production of NO might be the induction of an NO
synthase; thus, NO appears to be an important mediator
of the vascular actions of endotoxin and cytokines. Since
then, the role of NO in the pathogenesis of the
hyperdynamic circulation has been evaluated by several
groups of investigators in various animal models of
chronic liver disease. Most data support an important role
for NO in the development and maintenance as systemic
and splanchnic hemodynamic complications of chronic
liver disease (24).
In this study, we investigated the probable variability
of serum nitrite and nitrate levels in patients with chronic
hepatitis and cirrhosis.

Materials and Methods
Patients and samples
Forty hospitalized patients were included in this study,
of which 21 had chronic active hepatitis (mean age,
46±13). The etiology was hepatitis B in eight patients,
and hepatitis C in thirteen patients and nineteen patients
had cirrhosis (mean age, 51±8). The diagnosis of chronic
active hepatitis and cirrhosis was established on the basis
of clinical, analytical and ultrasonographic findings in all
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patients
observed
by
the
department
of
gastroenterology. No patient had received any previous
treatment. Ten healthy subjects with normal blood
pressure were used as controls after we ruled out liver,
kidney and heart disease. On the day of the study, all
patients were fasting and resting in bed. Blood samples
were collected at 8 AM in acid washed tubes. Following
coagulation, all samples were centrifuged at 4000xg for
10 minutes and sera were stored at -70¡C until
experiments.
Nitrite determination
The concentration of nitrite was determined with the
Griess reaction as described previously (25). All samples
were diluted fourfold with distilled water and
deproteinized by adding 1/20th volume of zinc sulfate
(300g/L) to give a final concentration of 15 g/L. After
centrifugation at 9500xg for 5 minutes at room
temperature, 150 µl of supernatant was applied to a
clean tube and 450µl of Griess reagent (1% sulfonilamide
in 1N HCl, 15% N-1-naphtyletylenediamine dichloride)
was added. After mixing well, all tubes were left in a dark
place for 30 minutes at room temperature. At the end of
the reaction time, the absorbances were measured on a
spectrophotometer (Jasco-500 /Japan) at a wavelength
of 550nm. A blank was prepared in the same way but
150µl potassium phosphate buffer (50mM) was used
instead of serum. Calibration curves were made with
sodium nitrite and potassium nitrate in distilled water
(linear range 0 Ð 100µmol/L).
Nitrate determination
Nitrate was measured as nitrite after enzymatic
conversion by nitrate reductase (EC1.6.6.2) as described
by Moshage (26). This procedure is based on the
reduction of all nitrate to nitrite and measured the sum of
nitrite concentration. Then the nitrate concentration was
calculated by subtracting the measured nitrite value from
the total nitrite concentration. 40 µl nitrate reductase
(20mU), 50 µl FAD (5mM), 10µl NADPH (0.6mM) and
250µl phosphate buffer (50mM) were added to 100µl
deproteinized samples prepared by mixing with 1/5 zinc
sulfate solution before the assay. The mixtures were
incubated for 1 hour at 37¡C, then 150µl of the mixture
was added to 450µl of Griess reagent and incubated
again for 30 min at room temperature. The absorbances
were measured on the spectrophotometer at a
wavelength of 550nm. To test the recovery of nitrite and
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nitrate in plasma, we used nitrite and nitrate calibration
curves made with normal plasma samples and with
hyperbilirubinemic and hemolytic plasma samples.
The results obtained from the patient and control
groups were analyzed statistically with the Mann-Whitney
U test.

Results

umol/L

The mean serum nitrite+nitrate, nitrate and nitrite
concentrations in cirrhosis, chronic active hepatitis and
control subjects were 84.8±9.43 µmol/L, 72.79±6.9
µmol/L and 29±4.6µmol/L; 74.75±9.49µmol/L,
59.9±7.09 µmol/L and 19.41±3.16 µmol/L,
10.03±1.59 µmol/L, 12.88±1.65 µmol/L, and
9.59±1.60 µmol/L respectively. Statistical evaluation
showed that nitrite+nitrate and nitrate levels were
increased in both patient groups compared with the
control group (p<0.0001) and a positive correlation was
found between these two parameters. However, there
was no significant difference in terms of nitrite levels
between the patient and control groups. Also no
significant difference was determined between
nitrite+nitrate and nitrate levels of the chronic hepatitis
and cirrhotic groups (p>0.5) (Figure).
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Total serum nitrite+nitrate, nitrate and nitrite concentrations
in patients and controls. Data are expressed as mean ±
standard deviation.

Discussion
This study demonstrates increased serum levels of
nitrite and nitrate, which are metabolites of nitric oxide,
in patients with cirrhosis. The initial cause of
overproduction of nitric oxide is not known, whereas

portal venous hypertension, which increases shear stress
and up-regulates endothelial nitric oxide synthase, no
doubt contributes to nitric oxide overproduction (27,28).
The concentrations of nitric oxide are higher in portal
venous plasma than in peripheral venous plasma in
patients with cirrhosis, suggesting increased splanchnic
production of nitric oxide (29). The activity of nitric oxide
synthase in polymorphonuclear cells and monocytes was
increased in patients who had cirrhosis. These cells mainly
contain the inducible type of nitric oxide synthase, a
finding that provides evidence that this type of the
enzyme may have a role in peripheral vasodilatation in
patients with cirrhosis (30). Nitric oxide production also
seems to be increased in patients with cirrhosis, but the
role of nitric oxide in the pathogenesis of arterial
vasodilatation and sodium and water retention in these
patients remains unclear (30,31).
We also found high nitrite and nitrate concentrations
in patients with chronic hepatitis. There is a discrepancy
between our results and reported studies, which
concluded that nitric oxide production was reduced or
unchanged in chronic hepatitis (32). However,
interestingly, these authors found even higher values of
nitrite and nitrate levels in patients with hepatocellular
carcinoma based on chronic hepatitis than in patients with
carcinoma accompanied by elevated plasma nitrite and
nitrate levels. These findings may suggest that some
chronic hepatitis patients have elevated serum nitrite and
nitrate concentrations, while some do not, and the reason
for this remains unclear (32). A possible explanation that
differences in the severity of inflammation and fibrosis
may cause varying serum nitrite and nitrate levels. Also
the etiology of chronic hepatitis may explain the
discrepancy between some previously reported studies
and our results.
In conclusion, serum nitrite and nitrate concentrations
may be elevated in patients with chronic hepatitis. This
increase may be due to enhanced cytokine expression, as
mentioned by Simpson et al. (33). Nitrite and nitrate
production also seems to be increased in patients with
cirrhosis, but the role of nitric oxide in the pathogenesis
of hemodynamic and renal abnormalities in patients with
cirrhosis remains unclear (34). If the experimental data
are confirmed, modulation of nitric oxide synthesis could
represent a new approach to management of circulatory
and renal dysfunction in patients with cirrhosis.
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